KPV: what the research says.
Last updated May 22, 2026
A three-amino-acid peptide (Lys-Pro-Val) corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone. Studied since the 1990s for anti-inflammatory effects in inflammatory bowel disease, skin inflammation, and cytokine modulation. Here is what the published evidence supports, and where the limits sit.
Regulatory notice: KPV is currently classified as an FDA Category 2 bulk drug substance. As of April 2026, licensed compounding pharmacies are not legally permitted to prepare or dispense it. KPV is not offered by PepScribe. This page is for educational purposes only and does not constitute medical advice or an offer to sell any product.
On February 27, 2026, the U.S. Department of Health and Human Services announced an intent to reclassify certain peptides, potentially including KPV. This announcement has not been formally published in the Federal Register and carries no legal effect until it is. Do not interpret this page as confirmation that KPV’s legal status has changed or that PepScribe will offer it in the future.
What KPV is.
KPV is a tripeptide composed of three amino acids: lysine, proline, and valine. The sequence corresponds to residues 11 to 13 (the C-terminal end) of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid endogenous peptide derived from proopiomelanocortin (POMC). Alpha-MSH itself has been studied for decades for its broad anti-inflammatory and immunomodulatory effects. Researchers identified KPV as the smallest fragment retaining a substantial portion of alpha-MSH’s anti-inflammatory activity while being shorter, more stable, and easier to synthesize.
The pivotal early work establishing alpha-MSH and KPV as anti-inflammatory agents came from James Lipton, Anna Catania, and colleagues. Their 1997 paper in Annals of the New York Academy of Sciences (Lipton, Catania, and Hadley) reviewed the anti-inflammatory and antipyretic actions of alpha-MSH across a series of preclinical models, and proposed that the C-terminal KPV sequence accounted for much of the activity. Subsequent peer-reviewed work has examined KPV in inflammatory bowel disease models, dermatology research, and cellular signaling studies.
How it works (proposed mechanisms).
Receptor-linked signaling
KPV is generally considered to act through the melanocortin signaling system. Alpha-MSH binds melanocortin receptors (MC1R through MC5R) expressed on immune cells, keratinocytes, and intestinal epithelial cells. Catania et al. (2004, Pharmacological Reviews) reviewed evidence that anti- inflammatory effects of alpha-MSH and its C-terminal fragments map to MC1R and MC3R expressed on macrophages, monocytes, and gut epithelium. KPV may also act intracellularly, independent of receptor binding, in some models.
Master inflammatory switch
Multiple studies report that KPV reduces nuclear translocation and transcriptional activity of NF-kB, a transcription factor central to inflammatory gene expression. Kannengiesser et al. (2008, Inflammatory Bowel Diseases) and follow-up work from the Merlin lab documented that KPV uptake into intestinal epithelial and immune cells via the PEPT1 transporter inhibits NF-kB signaling and reduces downstream inflammatory output.
Pro-inflammatory output
Preclinical work reports KPV reduces pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8 in stimulated immune and epithelial cells. Mastrofrancesco et al. (2010, Journal of Investigative Dermatology) examined alpha-MSH and KPV-related fragments in keratinocyte and sebocyte models, reporting reduced pro-inflammatory cytokine release after inflammatory challenge. The cytokine pattern observed in vitro parallels what is seen with broader melanocortin agonism.
Targeted gut delivery
Dalmasso, Charrier-Hisamuddin, et al. (2008, Gastroenterology) showed that KPV is transported into intestinal epithelial cells through PEPT1, the di- and tripeptide transporter that is upregulated in the inflamed colon. This finding is mechanistically interesting because it suggests an oral KPV formulation could selectively concentrate at sites of intestinal inflammation. The same group later reported colon-targeted nanoparticle delivery systems building on this principle.
Most mechanistic data is preclinical (cell culture and rodent models). The receptor versus intracellular contribution, the relevant dose, and the translation to human disease remain areas of active investigation rather than settled science.
What the research suggests.
KPV has a coherent preclinical evidence base in inflammatory bowel disease and skin inflammation. Large, randomized, placebo-controlled human trials are sparse, and translating animal findings to human clinical practice remains incomplete.
Inflammatory bowel disease (preclinical)
Travis et al. (2000, Annals of the New York Academy of Sciences) was among the first reports describing KPV-related anti-inflammatory effects in colitis-relevant models. Subsequent rodent work using DSS- and TNBS- induced colitis (Kannengiesser et al. 2008; Dalmasso et al. 2008) reported that oral or colon-targeted KPV reduced disease activity scores, weight loss, histological inflammation, and pro-inflammatory cytokine expression. Colon-targeted nanoparticle delivery using KPV (Laroui, Dalmasso, et al. 2010, Gastroenterology) further reduced systemic exposure while improving local efficacy in mice.
Dermatology and skin inflammation
Alpha-MSH and KPV-related fragments have been studied in keratinocyte, melanocyte, and sebocyte models. Mastrofrancesco et al. (2010, Journal of Investigative Dermatology) reported reduced inflammatory cytokine release in response to KPV-class fragments. Topical formulation research has explored applications in atopic dermatitis-like models, contact dermatitis, and acne-relevant sebocyte inflammation. Most of this work is preclinical or early-phase. Robust placebo-controlled human data is limited.
Allergic and mast-cell-mediated inflammation
Several preclinical studies have evaluated KPV in models relevant to allergic airway inflammation and mast-cell-driven responses. Reported effects include reduced mast cell degranulation and lower Th2 cytokine output in stimulated cell systems. As with the IBD literature, these findings come from animal and cellular work and have not been validated in adequately powered human clinical trials.
Wound healing context
Some research groups have placed KPV in the broader context of melanocortin effects on wound healing and tissue repair, alongside related peptides such as alpha-MSH and analogs. Reported in-vitro effects include altered fibroblast and keratinocyte behavior under inflammatory conditions. The data are early and should not be read as established clinical evidence for wound healing applications.
Administration (research context).
Research formulations of KPV have included oral capsules, colon-targeted nanoparticle systems (in animal studies), topical creams, and subcutaneous injection. The choice of route depends on the target tissue. PEPT1-mediated uptake in the inflamed colon is the basis for oral and gut-directed formulations, while topical preparations have been investigated for skin indications.
There is no internationally standardized clinical dose for KPV, because there is no FDA-approved indication. Dosing reported in preclinical research varies widely by route, formulation, and species, and does not translate directly to human prescribing.
This is research context, not prescribing guidance. PepScribe does not market KPV as a peptide-direct product, and this information should not be interpreted as a dosing recommendation.
Side effects & safety considerations.
The published safety profile is based largely on preclinical data and small, early-phase human studies. Long-term safety data from large randomized trials is not available.
Reported considerations
- Local injection-site reactions reported with subcutaneous use in some research
- Mild gastrointestinal complaints reported with oral formulations
- Possible local irritation with topical formulations
- Theoretical concerns about modulating endogenous melanocortin signaling, which has not been adequately studied in long-term human use
Safety profile notes
Preclinical toxicology of KPV is generally favorable in the published animal literature, with no major mutagenicity, carcinogenicity, or organ toxicity signals reported in the available studies. However, the absence of large placebo-controlled human trials means real-world safety in patients with active inflammatory disease, immunosuppression, pregnancy, or pediatric populations is not well characterized. Individual responses to peptide therapy vary.
Consult a licensed healthcare provider before considering any peptide therapy. This information is educational and does not replace clinical evaluation. Individual results may vary.
Legal status.
KPV is not approved by the FDA as a drug. There is no FDA-approved KPV product for any indication in the United States.
As of April 15, 2026, KPV was removed from the FDA’s Category 2 list as part of the broader compounding-policy reset, but it has not been placed on Category 1 or otherwise affirmatively cleared for routine compounding. KPV therefore sits in regulatory ambiguity: the prior categorical bar against compounding has been lifted in the most literal reading, but no FDA approval, no bioequivalence pathway, and no formal Pharmacy Compounding Advisory Committee (PCAC) decision is yet on the books. PCAC review is expected over July 23 to 24, 2026 for several Category-unclassified peptides, with the remainder reviewed by the end of February 2027.
Some 503A compounding pharmacies are preparing KPV under the “removal lifts prohibition” reading, while others are not, pending formal PCAC clarity. PepScribe treats KPV as consultation-first only: any clinical consideration is at the discretion of a licensed prescriber after evaluation, and PepScribe does not market KPV as a peptide-direct commercial product.
Gray-market vials and powders sold online as KPV without a prescription are research chemicals. They are unregulated, unverified for identity or purity, and outside the licensed compounding system.
Where it sits in clinical practice.
Practitioners who consider KPV typically do so in the context of inflammatory conditions of the gut or skin, where the published mechanistic and preclinical rationale is strongest. Because there are no large randomized human trials and no FDA-approved indication, any clinical use sits in an off-label, individual- practitioner-judgment space, not a guideline-driven one.
Within PepScribe’s model, KPV is not surfaced as a peptide-direct product. Patients with inflammatory or recovery-related goals are routed through a clinician-led consultation, where the prescriber decides what (if anything) is clinically appropriate based on the patient’s history, current condition, evidence quality, and the regulatory state of the relevant compound at the time of the visit.
NAD+
Supports cellular energy production and recovery-relevant pathways including sirtuin signaling and DNA repair. NAD+ is one of the FDA-cleared compounding options PepScribe offers under physician oversight, with delivery to your door.
Get startedSermorelin
A growth-hormone-releasing peptide that supports the body’s natural GH pulse, with downstream effects on sleep quality, recovery, and tissue repair. Physician-prescribed and within the standard compounding pathway.
Get startedDeep dives
More on KPV.
Research-backed articles covering specific topics in depth.
Talk to a clinician about your inflammatory or recovery goals.
KPV is not a peptide-direct product at PepScribe. The free assessment routes you to a licensed clinician who can evaluate your situation and discuss legal, evidence-based options.